Novartis: UBS still a buyer

(CercleFinance.com) - UBS considers the impact of the Kisqali production adjustments to be limited.
The analyst still confirms a Buy recommendation on the stock, with a target price of E104, representing 20% upside potential.

"Manufacturing adjustments are expected to be implemented by the end of 2Q and the regulatory review for NATALEE is to proceed as planned", UBS says.

Note that the group has revised its medium-term forecasts, now expecting net sales to rise by an average of 5% p.a. (at CER) over 2023-28, with a core operating profit margin growing by around 40% or more by 2027.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.